Search results for "Chronic"

showing 10 items of 3309 documents

Lack of hepatitis B virus DNA sequences in sera from patients with acute and chronic liver diseases diagnosed as non-A, non-B-hepatitis

2008

— The sera of 15 individuals with transfusion-associated acute or chronic non A, non B hepatitis, which lacked hepatitis B virus markers, were tested for hepatitis B virus DNA by dot blot hybridization test. Three sera of two patients positive in this test, however, also gave positive results when the labeled plasmid was used as probe instead of labeled HBV-DNA, indicating false positive results in the initial test. In conclusion, the data indicated that sera of patients with confirmed non A, non B hepatitis do not contain DNA-sequences in the serum hybridizing with HBV-DNA.

AdultMaleHepatitis B virusAdolescentHepatitis Viral HumanDot blotmedicine.disease_causeChronic liver diseaseVirusPlasmidmedicineHumansFalse Positive ReactionsAgedHepatitis B virusHepatologybiologybusiness.industryMiddle AgedHepatitis Bmedicine.diseasebiology.organism_classificationHepatitis CVirologyHepadnaviridaeDNA ViralImmunologyFemaleViral diseasebusinessLiver
researchProduct

Correlation of hepatitis B virus, hepatitis D virus and human immunodeficiency virus type I infection markers in hepatitis B surface antigen positive…

1992

The hepatitis D virus (HDV) infection plays a major role in severe liver damage caused by hepatitis. To establish the prevalence of HDV infection in haemophilic patients and patients without haemophilia, 87 patients with chronic hepatitis B virus (HBV) infection were examined for serological evidence of delta hepatitis. In addition HBV, HDV and human immunodeficiency virus type 1 (HIV) infection markers were compared to clinical and histopathological outcome of hepatitis. Out of 46 haemophiliacs 30 (65%) were anti-HD-seropositive; 10 out of 30 anti-HD-positive patients (33%) had pathological liver function tests compared to 2 out of 16 anti-HD-negative haemophiliacs (13%). The rate of HIV i…

AdultMaleHepatitis B virusCirrhosisAdolescentvirusesBiopsyRadioimmunoassaymedicine.disease_causeHaemophiliaHemophilia AmedicineHumansHepatitis AntibodiesHepatitis B e AntigensChildAntigens ViralHepatitis ChronicHepatitis B virusHepatitisAcquired Immunodeficiency SyndromeHepatitis B Surface Antigensbiologymedicine.diagnostic_testbusiness.industryvirus diseasesMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis BVirologyHepatitis DHepatitis DHepadnaviridaeLiverLiver biopsyChild PreschoolPediatrics Perinatology and Child HealthDNA ViralHepatitis D virusHepatitis Delta VirusbusinessEuropean journal of pediatrics
researchProduct

Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection

2002

Abstract OBJECTIVES: The virological profiles of hepatitis B and C viruses (HBV and HCV) and their interplay in cases of coinfection are undefined. A suppressed and occult HBV infection may occur in hepatitis B surface antigen (HBsAg) negative patients with chronic hepatitis C. The HCV core protein is able to inhibit HBV “in vitro,” and serines at positions 99 and 116 are essential for such inhibition. We aimed to assess the HBV and HCV virological profiles in cases of coinfection and to evaluate the relationship between HCV core gene variability and HBV activity. METHODS: Eighty-two anti-HCV positive patients were examined: 35 cases were HBsAg positive, 24 were HBsAg negative with “occult”…

AdultMaleHepatitis B virusHBsAgHCV RNAHepacivirusHepatitis C virusDUAL INFECTION; INTERFERON THERAPY; HEPATOCELLULAR-CARCINOMA; CHRONIC LIVER-DISEASE; HCV core protein; Hepatitis B Surface Antigens; HCV RNAGenome ViralHepacivirusDUAL INFECTIONVirus Replicationmedicine.disease_causeCHRONIC LIVER-DISEASEHepatitis B ChronicINTERFERON THERAPYOrthohepadnavirusHEPATOCELLULAR-CARCINOMAmedicineHumansAgedHepatitis B virusHepatitis B Surface AntigensHepatologybiologybusiness.industryHCV core proteinGastroenterologyvirus diseasesHepatitis C ChronicMiddle AgedViral LoadHepatitis Bbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesHepadnaviridaeDNA ViralImmunologyCoinfectionRNA ViralFemalebusinessThe American Journal of Gastroenterology
researchProduct

Clinical evaluation and applications of the Amplicor HBV Monitor™ test, a quantitative HBV DNA PCR assay

1998

Viral load has emerged recently as a reliable marker of disease progression and therapeutic efficacy in chronic infections, including AIDS and hepatitis C. The clinical management of type B hepatitis could also be improved by monitoring viremia levels in patients with chronic liver disease undergoing anti-viral treatment. To address this question we evaluated the performance of a newly developed, quantitative PCR assay (Amplicor HBV Monitor test, Roche Diagnostic Systems) in the assessment of viremia changes over time in a group of 45 patients with chronic active hepatitis (CAH) who received interferon treatment. Of the 45 patients, 14 were HBsAg and anti-HBeAg positive and 31 HBsAg, HBeAg …

AdultMaleHepatitis B virusHBsAgImmunoblottingViremiaBiologymedicine.disease_causePolymerase Chain ReactionHepatitis B ChronicVirologymedicineHumansHepatitis B e AntigensViremiaHepatitis B AntibodiesHepatitisHepatitis B virusHepatitis B Surface AntigensInterferon-alphavirus diseasesAlanine TransaminaseMiddle AgedViral LoadHepatitis Bmedicine.diseasebiology.organism_classificationVirologydigestive system diseasesTreatment OutcomeImmunoglobulin MHBeAgHepadnaviridaeEvaluation Studies as TopicDNA ViralImmunologyFemaleViral loadJournal of Virological Methods
researchProduct

Sustained response after lamivudine treatment in HBe minus chronic hepatitis B

2004

AdultMaleHepatitis B virusHepatologybusiness.industryLamivudineMiddle AgedVirologyAntiviral AgentsText miningHepatitis B ChronicChronic hepatitisLamivudineSustained responseDNA ViralMedicineHumansFemaleHepatitis B e Antigensbusinessmedicine.drug
researchProduct

Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection

2007

Summary Persistence of hepatitis B virus (HBV) infection is associated with reduced anti-viral T cell responses. Impaired dendritic cell (DC) function was suggested as the cause of reduced T cell stimulation in chronic HBV carriers. Thus, we compared myeloid (mDC) and plasmacytoid DC (pDC) from chronic HBV carriers and controls. Frequency and phenotype of isolated DC were analysed by fluorescence activated cell sorter staining, DC function by mixed lymphocyte reaction, cytokine bead array, intracellular cytokine staining, enzyme-linked immunosorbent assay and enzyme-linked immunospot. Expression of HBV DNA and mRNA was studied by polymerase chain reaction (PCR). Circulating total DC, mDC or…

AdultMaleHepatitis B virusHeterozygoteTranslational StudiesT cellImmunologyBone Marrow CellsLymphocyte Activationmedicine.disease_causeStatistics NonparametricVirusHepatitis B ChronicmedicineHumansImmunology and AllergyCytotoxic T cellLymphocyte CountHepatitis B virusbiologyDendritic CellsDendritic cellT helper cellHepatitis BFlow Cytometrybiology.organism_classificationmedicine.diseasemedicine.anatomical_structureHepadnaviridaeCase-Control StudiesDNA ViralImmunologyCytokinesRNA ViralFemaleLymphocyte Culture Test MixedT-Lymphocytes CytotoxicClinical and Experimental Immunology
researchProduct

Rare pre-core stop-codon mutant nt. 1897 predominates over wide-spread mutant nt. 1896 in an unusual course of chronic hepatitis B

1996

We present a patient with an unusual course of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B who had repeated reactivations of his disease progressing to cirrhosis with terminal liver failure. Each flare up presented like an acute hepatitis with very high titres of hepatitis B virus (HBV) and high inflammatory activity followed by rapid clearance of viraemia. The pre-core genome of HBV isolated from sera during 5 years of follow up was analysed. Direct sequencing of polymerase chain reaction (PCR) products derived from consecutive sera showed a rare pre-core stop-codon mutation at nucleotide (nt.) 1897 G --> A with an accompanying mutation nt. 1857 C --> T as well as a stop-cod…

AdultMaleHepatitis B virusMolecular Sequence DataMutantBiologymedicine.disease_causePolymerase Chain ReactionHepatitis B virus PRE betaVirusVirologymedicineHumansHepatitis B e AntigensHepatitis B AntibodiesHepatitis B virusMutationHepatitis B Surface AntigensBase SequenceHepatologyHepatitis BHepatitis B Core AntigensVirologyMolecular biologyStop codonInfectious DiseasesLiverViral replicationHBeAgChronic DiseaseDNA ViralMutationCodon TerminatorLiver FailureSignal TransductionT-Lymphocytes Cytotoxic
researchProduct

Immune blot analysis of viral surface proteins in serum and liver of patients with chronic hepatitis B virus infection

1989

The small and the middle surface proteins of hepatitis virus form either the virion or the 22 nm particle both of which are secreted. The large surface protein by itself remains cell bound in artificially transfected cell culture unless it is accompanied by an excess of the smaller protens. Its behavior in vivo is not yet well studied. Using specific monoclonal antibodies for immunoblotting, we found an abundance of small surface protein in the serum of chronic virus carriers and moderate amounts in the liver irrespective of viremia. The large surface protein was present in the serum and the liver of viremic carriers. In nonviremic carriers, the large protein was absent from serum, but in t…

AdultMaleHepatitis B virusmedicine.drug_classvirusesImmunoblottingBiologyMonoclonal antibodymedicine.disease_causeVirus03 medical and health sciences0302 clinical medicineViral envelopeVirologymedicineHumansAgedHepatitis Chronic030304 developmental biologyHepatitis B virusHepatitis0303 health sciencesHepatitis B Surface AntigensMiddle AgedHepatitis Bbiology.organism_classificationmedicine.diseaseVirologyMolecular biology3. Good healthBlotBloodInfectious DiseasesLiverHepadnaviridaeCell cultureFemale030211 gastroenterology & hepatologyJournal of Medical Virology
researchProduct

Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study

2010

To compare the management and the virological and serological efficacy of treatments for chronic hepatitis B (CHB) in HIV positive and negative patients.Two hundred and forty-six HIV positive and 205 HIV negative consecutive patients with past or present CHB, seen in October 2008 in participating departments, were included in a multicenter study. All the data were retrospectively collected from the first visit to October 2008 through a standardized questionnaire.Compared to HIV negative patients, HIV positive patients more often presented positive HBeAg (46.4% vs. 32.8%, p=0.01), HBV genotype A (54.8% vs. 17.1%, p0.0001), co-infection with HCV (12.4% vs. 5.9%, p=0.0002) or HDV (12.6% vs. 2.…

AdultMaleHepatitis B virusmedicine.medical_specialtyOrganophosphonatesHIV InfectionsAntiviral AgentsSerologyHepatitis B AntigensHepatitis B ChronicPharmacotherapyAcquired immunodeficiency syndrome (AIDS)Surveys and QuestionnairesInternal medicinemedicineHumansHepatitis B AntibodiesTenofovirSidaRetrospective StudiesHepatologybiologybusiness.industryAdeninevirus diseasesMiddle AgedHepatitis Bbiology.organism_classificationmedicine.diseaseHBeAgLentivirusImmunologyFemaleFranceViral diseasebusinessJournal of Hepatology
researchProduct

Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C

2003

Occult HBV infection in subjects with chronic hepatitis C is related to more severe disease outcome. It has been suggested that it might reduce sensitivity to antiviral treatment.To assess in HBsAg negative subjects with chronic hepatitis C any effect of the presence of HBV genomes in the liver on the early kinetics of HCV-RNA under PEG-IFN plus ribavirin.Twenty-two anti-HCV and HCV-RNA positive subjects, with biopsy-proven chronic hepatitis C (M/F 15/7; 50 +/- 8.6 years, 16 genotype 1b) were given PEG-IFN alpha 2b 1.0 microg qw plus ribavirin (800 to 1,200 mg daily according to body weight) for an intended 52 week period. Early virological response was assessed over the first 4 weeks of th…

AdultMaleHepatitis B viruspegylated interferon-alphaGenotypeBiopsyHepacivirusInterferon alpha-2Virus ReplicationAntiviral AgentsPolyethylene GlycolsHepatitis B AntibodieRibavirinchronic hepatitis CHumansHepatitis B AntibodiesAntiviral AgentHepaciviruoccult HBV infection; chronic hepatitis C; pegylated interferon-alpha; viral dynamics; treatment responseoccult HBV infectiontreatment responseInterferon-alphaAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesHepatitis C ChronicMiddle AgedRecombinant ProteinViral LoadHepatitis Bviral dynamicsRecombinant ProteinsTreatment OutcomeLiverDNA ViralRNA ViralDrug Therapy CombinationFemaleHepatitis C AntibodieHuman
researchProduct